Spring Advocacy Update: Educating, Advocating, and Building Momentum
A productive spring for Hope in Action: all Angelman syndrome priorities included in House FY27 appropriations reports, plus a new DOD grant opportunity now open thanks to your advocacy.
FAST Brings Angelman Syndrome Community Perspective to FDA Rare Disease Roundtable
FAST joined 15 advocacy groups at the FDA Rare Disease Roundtable this week, representing the Angelman syndrome community as therapies advance from research toward real-world development.
Call on Congress to Enact the FY2026 Defense Appropriations Act
FAST and ASF join a national coalition urging Congress to fully fund DOD medical research programs, protecting critical federal funding for Angelman syndrome research.
More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025
FAST attended this year’s ASGCT conference, where Angelman syndrome was featured in 10 scientific presentations and multiple talks—proof the community is helping drive the future of gene and cell therapy.